Can-Fite BioPharma Ltd. (CANF)
USD 1.33
(-6.34%)
USD 1.33
(-6.34%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.23 Million USD | -45.34% |
| 2022 | -2.91 Million USD | 31.65% |
| 2021 | -4.26 Million USD | 47.98% |
| 2020 | -8.2 Million USD | -212.78% |
| 2019 | -2.62 Million USD | 27.47% |
| 2018 | -3.61 Million USD | -3.38% |
| 2017 | -3.49 Million USD | 56.89% |
| 2016 | -8.11 Million USD | 52.04% |
| 2015 | -16.91 Million USD | -82.49% |
| 2014 | -9.26 Million USD | -55.43% |
| 2013 | -5.96 Million USD | -420.77% |
| 2012 | -1.14 Million USD | 70.19% |
| 2011 | -3.84 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -4.71 Million USD | 1.21% |
| 2024 Q1 | -4.71 Million USD | -11.35% |
| 2023 Q4 | -4.23 Million USD | -27.19% |
| 2023 FY | -4.23 Million USD | -45.34% |
| 2023 Q1 | -1.21 Million USD | 58.3% |
| 2023 Q2 | -3.39 Million USD | -178.95% |
| 2023 Q3 | -3.33 Million USD | 1.77% |
| 2022 Q1 | -5.39 Million USD | -26.47% |
| 2022 Q4 | -2.91 Million USD | 20.18% |
| 2022 Q3 | -3.65 Million USD | -124.8% |
| 2022 FY | -2.91 Million USD | 31.65% |
| 2022 Q2 | -1.62 Million USD | 69.88% |
| 2021 Q1 | -2.68 Million USD | 67.21% |
| 2021 Q4 | -4.26 Million USD | 25.21% |
| 2021 Q3 | -5.7 Million USD | -496.03% |
| 2021 Q2 | -957 Thousand USD | 64.41% |
| 2021 FY | -4.26 Million USD | 47.98% |
| 2020 Q1 | -5.73 Million USD | -118.84% |
| 2020 Q2 | -9 Million USD | -56.87% |
| 2020 FY | -8.2 Million USD | -212.78% |
| 2020 Q3 | -10.17 Million USD | -13.02% |
| 2020 Q4 | -8.2 Million USD | 19.38% |
| 2019 Q1 | -2.95 Million USD | 18.23% |
| 2019 Q4 | -2.62 Million USD | 44.0% |
| 2019 Q2 | -8.2 Million USD | -177.47% |
| 2019 Q3 | -4.68 Million USD | 42.92% |
| 2019 FY | -2.62 Million USD | 27.47% |
| 2018 FY | -3.61 Million USD | -3.38% |
| 2018 Q4 | -3.61 Million USD | 36.89% |
| 2018 Q3 | -5.72 Million USD | 1.92% |
| 2018 Q2 | -5.84 Million USD | 29.76% |
| 2018 Q1 | -8.31 Million USD | -137.75% |
| 2017 Q3 | -5.1 Million USD | 25.76% |
| 2017 Q2 | -6.87 Million USD | 29.67% |
| 2017 Q1 | -9.77 Million USD | -20.53% |
| 2017 FY | -3.49 Million USD | 56.89% |
| 2017 Q4 | -3.49 Million USD | 31.5% |
| 2016 FY | -8.11 Million USD | 52.04% |
| 2016 Q2 | -12.03 Million USD | 19.6% |
| 2016 Q4 | -8.11 Million USD | 18.94% |
| 2016 Q1 | -14.97 Million USD | 11.47% |
| 2016 Q3 | -10 Million USD | 16.88% |
| 2015 Q3 | -14.43 Million USD | -86.89% |
| 2015 Q2 | -7.72 Million USD | 14.34% |
| 2015 Q1 | -9.01 Million USD | 2.7% |
| 2015 Q4 | -16.91 Million USD | -17.15% |
| 2015 FY | -16.91 Million USD | -82.49% |
| 2014 Q1 | -7.82 Million USD | -31.3% |
| 2014 Q4 | -9.26 Million USD | -124.51% |
| 2014 Q3 | -4.12 Million USD | 26.13% |
| 2014 FY | -9.26 Million USD | -55.43% |
| 2014 Q2 | -5.58 Million USD | 28.62% |
| 2013 Q2 | -3.19 Million USD | 39.06% |
| 2013 Q3 | -2.71 Million USD | 15.26% |
| 2013 Q1 | -5.24 Million USD | -358.46% |
| 2013 FY | -5.96 Million USD | -420.77% |
| 2013 Q4 | -5.96 Million USD | -119.96% |
| 2012 Q1 | -2.75 Million USD | 28.32% |
| 2012 Q3 | -1.91 Million USD | 28.16% |
| 2012 Q4 | -1.14 Million USD | 40.05% |
| 2012 Q2 | -2.65 Million USD | 3.44% |
| 2012 FY | -1.14 Million USD | 70.19% |
| 2011 FY | -3.84 Million USD | 0.0% |
| 2011 Q4 | -3.84 Million USD | -705.08% |
| 2011 Q3 | -477.2 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -4.94 Million USD | 14.28% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -11.088% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 103.966% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 94.316% |
| Azitra, Inc. | -910.04 Thousand USD | -365.693% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 461.513% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 181.704% |
| CEL-SCI Corporation | 9.42 Million USD | 144.961% |
| iBio, Inc. | -9.75 Million USD | 56.533% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 86.956% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 40.733% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -230.835% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 1066.6% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -986.667% |
| NanoViricides, Inc. | -4.79 Million USD | 11.667% |
| Oragenics, Inc. | -3.17 Million USD | -33.657% |
| BiomX Inc. | -772 Thousand USD | -448.964% |
| BiomX Inc. | -772 Thousand USD | -448.964% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 260.106% |
| Palatin Technologies, Inc. | -8.93 Million USD | 52.579% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 130.584% |